Gobbling DNA Sciences, Genaissance Now Armed for Clinical Genotyping | GenomeWeb

In a move designed to bridge the gap between ho-hum upstream research and the rarefied world of clinical genotyping and diagnostics, Genaissance Pharmaceuticals has decided to buy all of the genotyping technologies and lab-based diagnostic products made by DNA Sciences.

The $1.3 million acquisition, announced in concert with DNA Sciences’ decision to seek Chapter 11 bankruptcy protection, makes Genaissance the first pharmacogenomics company to offer high-throughput haplotyping services along with a modest suite of commercialized CLIA- and GLP-rated tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.